Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Omacetaxine and Low Dose Cytarabine in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

Phase 2

Completed

Conditions: Leukemia

Interventions: Drug: Omacetaxine
Drug: Cytarabine

First Posted Date: 2011-01-07

Last Posted Date: 2018-05-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 36

Registration Number: NCT01272245

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Tasigna Neoadjuvant Gastrointestinal Stromal Tumor (GIST)

Phase 2

Withdrawn

Conditions: Gastrointestinal Cancer

Interventions: Drug: Nilotinib

First Posted Date: 2011-01-05

Last Posted Date: 2012-08-02

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT01270893

Wide-Field and High Resolution In Vivo Imaging in Visualizing Lesions in Patients With Oral Neoplasia Undergoing Surgery

Not Applicable

Recruiting

Conditions: Oral Cavity Neoplasm

Interventions: Procedure: High-Resolution Microendoscopy
Procedure: Multispectral Imaging
Drug: Proflavine

First Posted Date: 2011-01-04

Last Posted Date: 2025-04-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 275

Registration Number: NCT01269190

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Efficacy of NF-kB Inhibition for Reducing Symptoms During Maintenance Therapy in Multiple Myeloma Patients

Phase 2

Withdrawn

Conditions: Multiple Myeloma

Interventions: Other: Placebo
Drug: Curcumin

First Posted Date: 2011-01-04

Last Posted Date: 2012-09-07

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT01269203

Hypofractionated Radiation Therapy or Standard Radiation Therapy in Treating Patients With Ductal Breast Carcinoma In Situ or Early Invasive Breast Cancer

Phase 2

Active, not recruiting

Conditions: Ductal Breast Carcinoma In Situ
Stage IIA Breast Cancer AJCC v6 and v7
Stage IIB Breast Cancer AJCC v6 and v7
Stage IA Breast Cancer AJCC v7
Stage II Breast Cancer AJCC v6 and v7
Stage I Breast Cancer AJCC v6
Stage IB Breast Cancer AJCC v7
Invasive Breast Carcinoma

Interventions: Radiation: External Beam Radiation Therapy
Radiation: Hypofractionated Radiation Therapy
Other: Laboratory Biomarker Analysis
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Radiation: Whole Breast Irradiation

First Posted Date: 2010-12-24

Last Posted Date: 2025-02-17

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 301

Registration Number: NCT01266642

Locations: 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸
MD Anderson West Houston, Houston, Texas, United States

and more 4 locations

Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer

Phase 1

Completed

Conditions: Advanced Cancers

Interventions: Drug: Hydroxychloroquine
Drug: Vorinostat
Drug: Sirolimus

First Posted Date: 2010-12-24

Last Posted Date: 2021-03-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 143

Registration Number: NCT01266057

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

TKI 258 in Von Hippel-Lindau Syndrome (VHL)

Phase 2

Terminated

Conditions: Von Hippel-Lindau Syndrome

Interventions: Drug: Dovitinib

First Posted Date: 2010-12-24

Last Posted Date: 2017-02-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 6

Registration Number: NCT01266070

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Controlled Trial of Acupuncture to Prevent Radiation-Induced Xerostomia

Phase 3

Active, not recruiting

Conditions: Head and Neck Cancer

Interventions: Procedure: Acupuncture - Group 1
Procedure: Acupuncture - Group 2
Other: Standard Care
Other: Questionnaire

First Posted Date: 2010-12-24

Last Posted Date: 2024-10-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 435

Registration Number: NCT01266044

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇨🇳
Fudan University Cancer Hospital, Shanghai, China

High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI

Phase 2

Completed

Conditions: Melanoma

Interventions: Drug: HDIL-2
Biological: recMAGE-A3 + AS15

First Posted Date: 2010-12-24

Last Posted Date: 2020-02-19

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 44

Registration Number: NCT01266603

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Neoadjuvant Axitinib in Locally Advanced Renal Cell Carcinoma (RCC)

Phase 2

Completed

Conditions: Kidney Cancer

Interventions: Drug: Axitinib

First Posted Date: 2010-12-21

Last Posted Date: 2024-01-03

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 39

Registration Number: NCT01263769

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy